6392-97-8

Basic information

• Product Name: 2-Phenyl-benzothiazol-6-ylamine
• Synonyms: 2-Phenylbenzo[d]thiazol-6-amine
• CAS NO: 6392-97-8
• Molecular Formula: C₁₃H₁₀N₂S
• Molecular Weight: 226.297
• Mol File: 6392-97-8.mol
• Article Data: 9

Chemical Properties

• Melting Point: 206-207 °C
• Boiling Point: 430.9 °C at 760 mmHg
• Flash Point: 214.4 °C
• Appearance: /
• Density: 1.301 g/cm³
• PKA: 2?+-.0.10(Predicted)
• CAS DataBase Reference: 2-Phenyl-benzothiazol-6-ylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Phenyl-benzothiazol-6-ylamine(6392-97-8)
• EPA Substance Registry System: 2-Phenyl-benzothiazol-6-ylamine(6392-97-8)

Safety Data

• Hazardous Substances Data: 6392-97-8(Hazardous Substances Data)

Usage

General Description

2-Phenyl-benzothiazol-6-ylamine is a chemical compound with the molecular formula C14H11NOS. It is a member of the benzothiazole family and consists of a benzothiazole ring with an attached phenyl group and an amine functional group. 2-Phenyl-benzothiazol-6-ylamine is used in organic synthesis and pharmaceutical research as a building block for the production of various compounds with potential biological activity. It can also be used as a probe in studies of enzyme kinetics and drug receptor interactions. The compound may have potential applications in the development of new drugs and therapeutic agents due to its structural and functional properties.

Upstream product

• 38338-23-7 6-nitro-2-phenyl-benzothiazole 
• 64-17-5 ethanol 
• 93930-09-7 thiosulfuric acid S-(2,5-diamino-phenyl ester) 
• 100-52-7 benzaldehyde 
• 23451-98-1 2-amino-5-nitrobenzenethiol 
• 98-88-4 benzoyl chloride 
• 2516-37-2 2-bromo-6-nitro-benzo[d]thiazole 
• 945400-80-6 2-bromanyl-1,3-benzothiazol-6-amine 
• 24388-23-6 2-phenyl-4,4,5,5-tetramethyl-1,3,2-dioxoborole 
• 6285-57-0 2-amino-6-nitrobenzothiazole 
• 95-16-9 1,3-Benzothiazole 
• 2942-06-5 6-nitrobenzo[d]thiazole 
• 533-30-2 1,3-benzothiazol-6-amine 
• 108-86-1 bromobenzene 

Downstream Products

• 863770-37-0 N-(2-phenylbenzothiazol-6-yl)acetamidine 
• 1426262-48-7 C₁₅H₁₁ClN₂OS 
• 1426262-52-3 C₂₈H₃₂N₄O₂S₂ 
• 1426262-55-6 C₂₈H₃₄N₄OS₂ 

Relevant articles and documents

Design, synthesis and biological evaluation of new benzoxazolone/benzothiazolone derivatives as multi-target agents against Alzheimer's disease

In this study, four series of compounds with benzoxazolone and benzothiazolone cores were designed, synthesized and evaluated as multifunctional agents against Alzheimer's disease (AD). Additionally, in order to shed light on the effect of the carbonyl groups of benzoxazolone/benzothiazolone, benzoxazole/benzothiazole-containing analogues were also synthesized and evaluated. Inhibition potency of all final compounds towards cholinesterase enzymes and their antioxidant activity were tested. Subsequently, the anti-inflammatory activity, cytotoxicity, apoptosis, and Aβ aggregation inhibition tests were also performed for selected compounds. The results indicated that compounds 11c, a pentanamide derivative with benzothiazolone core, and 14b, a keton derivative with benzothiazolone core, were considered as promising multi-functional agents for further investigation against AD. The reversibility, kinetic and molecular docking studies were also performed for the compounds with the highest AChE 14b (eeAChE IC50 = 0.34 μM, huAChE IC50 = 0.46 μM) and BChE 11c (eqBChE IC50 = 2.98 μM, huBChE IC50 = 2.56 μM) inhibitory activities.

NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF

The present invention relates to novel hydrazone derivatives in which a terminal amine group is substituted with an aryl group or a heteroaryl group, and uses thereof.

Design, synthesis and structure-activity relationship of rhenium 2-arylbenzothiazoles as β-amyloid plaque binding agents

To continue our efforts toward the development of 99mTc PiB analogs, we have synthesized 24 neutral and lipophilic Re (as a surrogate of 99mTc) 2-arylbenzothiazoles, and explored their structure-activity relationship for binding to Aβ1-40 fibrils. These Re complexes were designed and synthesized via the integrated approach, so their 99mTc analogs would have a greater chance of crossing the blood-brain barrier. While the lipophilicities (log PC18 = 1.59-3.53) of these Re 2-arylbenzothiazoles were all within suitable range, their binding affinities (Ki = 30-617 nM) to Aβ1-40 fibrils varied widely depending on the selection and integration of the tetradentate chelator into the 2-phenylbenzothiazole pharmacophore. For potential clinical applications, further refinement to obtain Re 2-arylbenzothiazoles with better binding affinities (99mTc analogs for more widespread application via the use of SPECT scanners.